Search results
Showing 551 to 600 of 798 results for team work
Botulinum toxin type A for preventing episodic migraine [ID6450]
In development Reference number: GID-TA11505 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)
Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.
View recommendations for IPG754Show all sections
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420
This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open-angle glaucoma and ocular hypertension and on effective diagnosis, treatment and reassessment to stop these conditions progressing.
Discontinued Reference number: GID-TAG280
In development Reference number: GID-TA11607 Expected publication date: 13 January 2027
Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant (IPG795)
Evidence-based recommendations on direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. This involves inserting a metal implant through the skin and into the centre of the bone of the stump and attaching a prosthetic limb to it.
View recommendations for IPG795Show all sections
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
Discontinued Reference number: GID-TAG424
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
Discontinued Reference number: GID-TAG425
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
Discontinued Reference number: GID-TAG433
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
In development Reference number: GID-MT538 Expected publication date: TBC
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
Discontinued Reference number: GID-TAG278
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development Reference number: GID-TA10822 Expected publication date: TBC
Discontinued Reference number: GID-TAG437
In development Reference number: GID-TA11585 Expected publication date: TBC
New pharmaceutical treatments for non-Alzheimer dementias [ID380]
Discontinued Reference number: GID-TAG369
Discontinued Reference number: GID-TA10663
Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.
In development Reference number: GID-TA11146 Expected publication date: TBC
In development Reference number: GID-HST10020 Expected publication date: TBC
Discontinued Reference number: GID-TA10841
Our system implementation team works with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area, ensuring regular interaction with our stakeholders.
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued Reference number: GID-TAG411
In development Reference number: GID-TA11345 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued Reference number: GID-TAG416
In development Reference number: GID-TA11679 Expected publication date: TBC
In development Reference number: GID-TA10696 Expected publication date: TBC
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
Discontinued Reference number: GID-TAG409
In development Reference number: GID-TAG406 Expected publication date: TBC
This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued Reference number: GID-TA10087
Discontinued Reference number: GID-TAG390
Intensity modulated radiotherapy for head and neck cancer [ID15]
Discontinued Reference number: GID-TAG397
Discontinued Reference number: GID-TAG396
Discontinued Reference number: GID-CGWAVE0773
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
In development Reference number: GID-TA11310 Expected publication date: TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099
In development Reference number: GID-TA11640 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
Discontinued Reference number: GID-TAG221
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .